Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017 Mar 27, 2018 4:15pm EDT
Aptose to Present New CG’806 and APTO-253 Data at the 2018 AACR Annual Meeting Mar 15, 2018 7:05am EDT
Aptose To Release Fourth Quarter and Year End December 31, 2017 Financial Results and Hold Conference Call on March 27, 2018 Mar 08, 2018 7:00am EST
Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology Mar 07, 2018 7:00am EST
Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus Feb 07, 2018 4:01pm EST
FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia Dec 26, 2017 7:30am EST
Aptose Presents New Preclinical Data on CG’806 pan-FLT3/pan-BTK Inhibitor at ASH 59th Annual Meeting Dec 11, 2017 4:04pm EST
